A human-specific antibody selectively inhibits interleukin-6 trans-signalling while preserving classic signalling, revealing distinct receptor assembly mechanisms.
- Open access
Moving in bioRxiv, Communications Biology, Cell Host & Microbe, eLife, Nature Immunology and Nature Reviews Drug Discovery.
Rebuilt
Nothing in this topic has moved yet this week.
Newest first · last 60 days
A human-specific antibody selectively inhibits interleukin-6 trans-signalling while preserving classic signalling, revealing distinct receptor assembly mechanisms.
High JAK-STAT pathway activity in breast cancer correlates with improved immunotherapy response, especially in triple-negative breast cancer patients, serving as a predictive biomarker.
A 12-amino-acid stretch within the STAT5 transactivation domain is essential for its nuclear import, with residues D754 and D758 being critical for this process.
Selective targeting of IL-6 trans-signalling may improve safety and efficacy in treating inflammatory diseases by differentiating from classic signalling pathways.
Strong, sustained type I IFN signaling intrinsically impairs IFNγ responses in macrophages, increasing susceptibility to tuberculosis in Mycobacterium tuberculosis infection.
Journals this month
Topics moving, week to 22 Oct 2026